[1]
|
[1] Chen, Y.E. and Drucker, D. (1997) Tissue-Specific Expression of Unique mRNAs that Encode Pro-Glucagon-Derived Peptides or Exendin-4 in the Lizard. The Journal of Biological Chemistry, 272, 4108-4115.
|
[2]
|
Drucker, D.J. (1998) Glucagon-Like Peptides. Diabetes, 47, 159-169.
https://doi.org/10.2337/diab.47.2.159
|
[3]
|
Young, A.A., Gedulin, B.R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B. and Denaro, M. (1999) Glucose-Lowering and Insulin-Sensitizing Actions of Exendin-4: Studies in Obese Diabetic (ob/ob, dbh/db) Mice, Diabetic Fatty Zucker Rats, and Diabetic Rhesus Monkeys (Macaca mulatta). Diabetes, 48, 1026-1034.
https://doi.org/10.2337/diabetes.48.5.1026
|
[4]
|
Parkes, D.G., Pittner, R., Jodka, C., Smith, P. and Young, A. (2001) Insulinotropic Actions of Exendin-4 and Glucagon-Like Peptide-1 in Vivo and in Vitro. Metabolism, 50, 583–589. https://doi.org/10.1053/meta.2001.22519
|
[5]
|
Nielsen, L.L. and Baron, A.D. (2003) Pharmacology of Exenatide (Synthetic Exendin-4) for the Treatment of Type 2 Diabetes. Current Opinion in Investigational Drugs, 4, 401-405.
|
[6]
|
Nielsen, L.L., Young, A.A. and Parkes, D. (2004) Pharmacology of Exenatide (Synthetic Exendin-4): A Potential Therapeutic for Improved Glycemic Control of Type Diabetes. Regulatory Peptides, 117, 77-88.
https://doi.org/10.1016/j.regpep.2003.10.028
|
[7]
|
Bunck, M.C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J.L., Shaginian, R.M., Deng, W. and Kendall, D.M. (2009) One-Year Treatment With Exenatide Improves β-Cell Function, Compared with Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients. Diabetes Care, 32, 762-768. https://doi.org/10.2337/dc08-1797
|
[8]
|
Szayna, M., Doyle, M.E., Betkey, J.A., Holloway, H.W., Spencer, R.G.S., Greig, N.H. and Egan, J.M. (2000) Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats. Endocrinology, 141, 1936-1941.
https://doi.org/10.1210/endo.141.6.7490
|
[9]
|
Edwards, C.M., Stanley, S.A., Davis, R., Brynes, A.E., Frost, G.S., Seal, L.J., Ghatei, M.A. and Bloom, S.R. (2001) Exendin-4 Reduces Fasting and Postprandial Glucose and Decreases Energy Intake in Healthy Volunteers. American Journal of Physiology-Endocrinology and Metabolism, 281, E155-E161.
https://doi.org/10.1152/ajpendo.2001.281.1.E155
|
[10]
|
Poon, T., Nelson, P., Shen, L., Mihm, M., Taylor, K., Fineman, M. and Kim, D. (2005) Exenatide Improves Glycemic Control and Reduces Body Weight in Subjects with Type 2 Diabetes: A Dose-Ranging Study. Diabetes Technology & Therapeutics, 7, 467-477.
|
[11]
|
DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D. (2005) Effects of Exenatide (Exendin-4) on Glycemic Control and Weight over 30 Weeks in Metformin-Treated Patients with Type 2 Diabetes. Diabetes Care, 28, 1092-1100. https://doi.org/10.2337/diacare.28.5.1092
|
[12]
|
Blonde, L., Klein, E.J., Han, J., Zhang, B., Mac, S.M., Poon, T.H., Taylor, K.L., Trautmann, M.E., Kim, D.D. and Kendall, D.M. (2006) Interim Analysis of the Effects of Exenatide Treatment on A1C, Weight and Cardiovascular Risk Factors over 82 Weeks in 314 Overweight Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 8, 436–447. https://doi.org/10.1111/j.1463-1326.2006.00602.x
|
[13]
|
Ratner, R.E., Maggs, D., Nielsen, L.L., Stonehouse, A.H., Poon, T., Zhang, B., Bicsak, T.A., Brodows, R.G. and Kim, D.D. (2006) Long-Term Effects of Exenatide Therapy over 82 Weeks on Glycaemic Control and Weight in Over-Weight Metformin-Treated Patients with Type 2 Diabetes Mellitus. Diabetes, Obesity and Metabolism, 8, 419-428. https://doi.org/10.1111/j.1463-1326.2006.00589.x
|
[14]
|
Klonoff David, C., Buse John, B., Nielsen Loretta, L., Guan, X.S., Bowlus Christopher, L., Holcombe, J.H., Wintle Matthew, E. and Maggs, D.G. (2008) Exenatide Effects on Diabetes, Obesity, Cardiovascular Risk Factors and Hepatic Biomarkers in Patients with Type 2 Diabetes Treated for at Least 3 Years, Current Medical Research and Opinion, 24, 275-286.
https://doi.org/10.1185/030079908X253870
|
[15]
|
Kolterman, O.G., Buse, J.B., Fineman, M.S., Gaines, E., Heintz, S., Bicsak, T.A., Taylor, K., Kim, D., Aisporna, M., Wang, Y. and Baron, A.D. (2003) Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 88, 3082-3089. https://doi.org/10.1210/jc.2002-021545
|
[16]
|
Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D., Exenatide-113 Clinical Study Group (2004) Effects of Exenatide (Exendin-4) on Glycemic Control over 30 Weeks in Sulfonylurea-Treated Patients with Type 2 Diabetes. Diabetes Care, 27, 2628-2635. https://doi.org/10.2337/diacare.27.11.2628
|
[17]
|
John, L.E., Kane, M.P., Busch, R.S. and Hamilton, R.A. (2007) Expanded Use of Exenatide in the Management of Type 2 Diabetes. Diabetes Spectrum, 20, 59-63.
https://doi.org/10.2337/diaspect.20.1.59
|
[18]
|
American Diabetes Association (2018) Glycemic Targets: Standards of Medical Care in Diabetes. Diabetes Care, 43, S55-S64.
|
[19]
|
Louis, L.M., Lapinski, H. and Claude, C. (2003) Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients. Diabetes Care, 26, 881-885.
https://doi.org/10.2337/diacare.26.3.881
|
[20]
|
Sonal, B. and Udaya, K. (2017) Eleavated Pancreatic Enzymes and Acute Pancreatitis in Subjects with Type 2 Diabetes Treated with Exenatide. Advanced Research in Gastroenterology and Hepatology, 1, 1-4.
|
[21]
|
Kabadi, U.M. and Kabadi, M.U. (2001) Improvement in Lipids with Glimepiride in Type 2 Diabetes Mellitus. Diabetes Research, 35, 155.
|
[22]
|
Kabadi, U.M. (2004) Weight Gain, Improvement in Metabolic Profiles and Immunogenicity with Insulin or Sulfonylurea Administration in AIDS. Clinical Drug Investigation, 24, 287-294. https://doi.org/10.2165/00044011-200424050-00005
|
[23]
|
Kabadi, U.M. (2006) Comparative Efficacy of Glimepiride and/or Metformin with Insulin in Type 2 Diabetes. Diabetes Research & Clinical Practice, 72, 265-270.
https://doi.org/10.1016/j.diabres.2005.10.024
|
[24]
|
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., Byington, R.P., Goff Jr., D.C., Bigger, J.T., Buse, J.B., Cushman, W.C., Genuth, S., Ismail-Beigi, F., Grimm Jr., R.H., Probstfield, J.L., Simons-Morton, D.G. and Friedewald, W.T. (2008) Effects of Intensive Glucose Lowering in Type 2 Diabetes. The New England Journal of Medicine, 358, 2545-2559.
|
[25]
|
Esmail, R. and Kabadi U.M. (2016) Improvement in Cardiovascular Risk Markers with Glimepiride in Non Obese Subjects with Pre Diabetes: Similar to Obese Cohort Treated with Metformin. British Journal of Medicine & Medical Research, 18, 1-6.
|
[26]
|
Fritsche, A., Schweitzer, M.A., Häring, H.U., 4001 Study Group (2003) Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes: A Randomized, Controlled Trial. Annals of Internal Medicine, 138, 952-959.
https://doi.org/10.7326/0003-4819-138-12-200306170-00006
|
[27]
|
Standl, E., Maxeiner, S., Raptis, S., Karimi-Anderesi, Z., Schweitzer, M.A., HOE901/4009 Study Group (2005) Good Glycemic Control with Flexibility in Timing of Basal Insulin Supply: A 24-Week Comparison of Insulin Glargine Given Once Daily in the Morning or at Bedtime in Combination with Morning Glimepiride. Diabetes Care, 28, 419-420. https://doi.org/10.2337/diacare.28.2.419
|
[28]
|
Kabadi, U.M. (2016) Better Glycemic Control with Lesser Hypoglycemia on Transition of Insulin Glargine Administration at Bedtime to Morning in Type 2 Diabetes Mellitus. Diabetes Research and Metabolism, 1, 1-7.
|
[29]
|
Hampton, N., Exley, S., Robbins, S. and Kabadi, U.M. (2018) Lower Daily Dose with Better Outcomes with Oral Agents and AM Insulin Toujeo Administration than Lantus While Attaining Desirable Glycemic Control in Type 2 Diabetes. European Journal of Pharmaceutical and Medical Research, 5, 555-563.
|